Concepedia

Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies

Thomas Langbein, Guillaume Chaussé, Richard P. Baum

Journal of Nuclear Medicine · 2018 · 99 citations · 13 references

DOIFull text

Open access

Concepts

Abstract

Since the first clinical use of 131I-labeled prostate-specific membrane antigen (PSMA) ([1][1]), xerostomia has been identified as a relevant side effect of PSMA radioligand therapies (PRLTs) for metastatic castration-resistant prostate cancer. Given the remarkable progress when using 177Lu-labeled

References

13

German Multicenter Study Investigating<sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil et al. · Journal of Nuclear Medicine · 2016 · 812 citations · Full text

<sup>177</sup>Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2016 · 518 citations · Full text

Phase I Trial of <sup>177</sup>Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

Neil H. Bander, Matthew I. Milowsky, David M. Nanus et al. · Journal of Clinical Oncology · 2005 · 504 citations

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup>Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control

Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke et al. · Journal of Nuclear Medicine · 2018 · 413 citations · Full text

Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

Christian M. Zechmann, Ali Afshar‐Oromieh, Tom Armor et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 349 citations · Full text